Understanding the goals of CAD treatment1-4

Current management of CAD
Current management of CAD does not directly target haemolysis—the source of patient risk. Cold avoidance is ineffective at managing symptoms and unapproved therapies have inherent limitations. There is an unmet need for treatment options designed for CAD that address C1-activated haemolysis.

The goals of future treatment should include:

haemoglobin icon

Increase in haemoglobin levels

Transfusion independence icon

Achievement of transfusion independence

Circulatory symptoms icon

Improvement or resolution of cold-induced circulatory symptoms

Quality of life icon

Improved quality of life

Rescue therapy icon

Rescue therapy for emergency situations

Future treatment5

Research is ongoing for new treatment options that will address the consequences of CAD.

Sanofi is committed to breaking barriers through groundbreaking science to significantly improve the health and lives of people with rare blood disorders around the world.

Clipboard icon

There are specific criteria to diagnose CAD

C1 activated haemolysis

In CAD, activated C1 drives chronic haemolysis

CAD=Cold Agglutinin Disease.

References: 1. Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122(7):1114-1121. doi:10.1182/blood-2013-02-474437 2. Mullins M, Jiang X, Bylsma LC, et al. Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization. Blood Adv. 2017;1(13):839-848. doi:10.1182/bloodadvances.2017004390 3. Berentsen S, Tjønnfjord GE. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev. 2012;26(3):107-115. 4. Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648. doi:10.1016/j.blre.2019.100648 5. Berentsen S. New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia. Front Immunol. 2020;11:590. doi:10.3389/fimmu.2020.00590